STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec®/ Gleevec®) 400 mg daily versus dasatinib (Sprycel®) 100 mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukaemia
ISRCTN | ISRCTN54923521 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN54923521 |
EudraCT/CTIS number | 2007-006185-15 |
ClinicalTrials.gov number | NCT01460693 |
Secondary identifying numbers | 4443 |
- Submission date
- 17/04/2008
- Registration date
- 09/10/2008
- Last edited
- 20/03/2020
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Contact information
Ms Corinne Hedgley
Scientific
Scientific
Newcastle University
Academic Haematology
School of Clinical & Laboratory Sciences
Leech Building, Medical School
Framlington Place
Newcastle upon Tyne
NE2 4HH
United Kingdom
Phone | +44 (0)1280 814 916 |
---|---|
c.a.hedgley@ncl.ac.uk |
Study information
Study design | Phase III, multicentre, open-label, prospective randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | STI571 Prospective International RandomIsed Trial 2: A phase III, prospective randomised comparison of imatinib (STI571, Glivec®/ Gleevec®) 400 mg daily versus dasatinib (Sprycel®) 100 mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukaemia |
Study acronym | SPIRIT 2 |
Study objectives | To compare 5-year Event Free Survival (EFS) between the treatment arms. The study is powered to demonstrate superiority of the dasatinib arm over the imatinib arm. |
Ethics approval(s) | London Research Ethics Committee in 11/2007 (ref: 07/H0718/90) |
Health condition(s) or problem(s) studied | Newly diagnosed, chronic-phase, chronic myeloid leukaemia |
Intervention | Arm 1: Imatinib (oral) 400 mg daily, to be taken for a minimum of 5 years Arm 2: Dasatinib (oral) 100 mg daily, to be taken for a minimum of 5 years All endpoints will be assessed at regular timepoints throughout the trial for a minimum of 5 years per patient. Contact details of Principal Investigator: Dr Stephen O'Brien Newcastle University Academic Haematology School of Clinical & Laboratory Sciences Leech Building, Medical School Framlington Place Newcastle upon Tyne NE2 4HH United Kingdom |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Phase III |
Drug / device / biological / vaccine name(s) | STI571 (Glivec®/ Gleevec®) and dasatinib (Sprycel®). |
Primary outcome measure | Event -free survival at 5 years |
Secondary outcome measures | 1. To compare the rate of complete cytogenetic response after 2 years 2. To compare the treatment failure rates (TFR) at 5 years 3. To compare the rates of complete haematologic response (CHR). Duration of follow-up: 60 months 4. To compare the level of 'molecular' response (BCR-ABL/ABL ratio by real time polymerase chain reaction [PCR]). Duration of follow-up: 60 months 5. To compare the tolerability between the regimens. This will in part be incorporated into the treatment failure assessment. Duration of follow-up: 60 months 6. To assess quality of life by the EQ-5D and the Functional Assessment of Cancer Treatment-Biological Response Modifier (FACT-BRM) questionnaires. Timepoints of assessment: at screening and then Months 1, 2, 3, 6, 12, 24, 36, 48, 60 7. To assess the broad comparative costs between the regimens 8. To compare overall survival at 2 and 5 years |
Overall study start date | 30/06/2008 |
Completion date | 30/06/2016 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | 810 |
Key inclusion criteria | 1. Male or female patients >= 18 years of age 2. Patients must have all of the following: 2.1. Be enrolled within 3 months of initial diagnosis of chronic myeloid leukaemia - chronic phase (CML-CP) (date of initial diagnosis is the date of first cytogenetic analysis) 2.2. Cytogenetic confirmation of the Philadelphia chromosome or variants of (9;22) translocations; patients may have secondary chromosomal abnormalities in addition to the Philadelphia chromosome 2.3. <15% blasts in peripheral blood and bone marrow 2.4. <30% blasts plus promyelocytes in peripheral blood and bone marrow 2.5. <20% basophils in peripheral blood 2.6. >= 100 x 10^9/L platelets 2.7. No evidence of extramedullary leukaemic involvement, with the exception of hepatosplenomegaly 3. Written voluntary informed consent |
Key exclusion criteria | 1. Patients with Ph-negative, BCR-ABL-positive disease are not eligible for the study 2. Any prior treatment for CML with: any tyrosine kinase inhibitor (e.g., imatinib, dasatinib, nilotinib); busulphan; interferon-alpha; homoharringtonine; cytosine arabinoside; any other investigational agents (hydroxycarbamide and anagrelide are the only drugs permitted). NB: Patients will be ineligible for the study if they have received any prior therapy with interferon-alpha or imatinib. No exceptions. 3. Patients who received prior chemotherapy, including regimens used in peripheral blood progenitor cells (PBPCs) mobilisation for haematopoietic progenitor-cell transplantation (It is allowable to collect unmobilised PBPCs at diagnosis) 4. Patient who have had any form of prior haemopoietic stem cell transplant, either autograft or allograft 5. Patients with an Eastern Cooperative Oncology Group (ECOG) Performance Status Score >= 3 6. Patients with serum bilirubin, aspartate aminotransferase (SGOT/AST), alanine aminotransferase (SGPT/ALT), or creatinine concentrations > 2.0 x the institutional upper limit of the normal range (IULN) 7. Patients with International normalised ratio (INR) or partial thromboplastin time (PTT) >1.5 x IULN, with the exception of patients on treatment with oral anticoagulants 8. Patients with uncontrolled medical disease such as diabetes mellitus, thyroid dysfunction, neuropsychiatric disorders, infection, angina, or Grade 3/4 cardiac problems as defined by the New York Heart Association Criteria 9. Patients with known positivity for human immunodeficiency virus (HIV); baseline testing for HIV is not required 10. Patients who have undergone major surgery within 4 weeks of Study Day 1, or who have not recovered from prior major surgery 11. Patients who are: 11.1 Pregnant 11.2. Breast feeding 11.3. Of childbearing potential without a negative pregnancy test prior to Study Day 1 11.4. Male or female of childbearing potential unwilling to use barrier contraceptive (Amenorrhoeic for at least 12 months to be considered of non-childbearing potential) 12. Patients with a history of another malignancy either currently or within the past five years, with the exception of basal cell skin carcinoma or cervical carcinoma in situ 13. Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable |
Date of first enrolment | 30/06/2008 |
Date of final enrolment | 30/06/2016 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Newcastle University
Newcastle upon Tyne
NE2 4HH
United Kingdom
NE2 4HH
United Kingdom
Sponsor information
Newcastle-upon-Tyne Hospitals NHS Foundation Trust (UK)
Hospital/treatment centre
Hospital/treatment centre
R&D Department
4th Floor
Leazes Wing
Royal Victoria Infirmary
Queen Victoria Road
Newcastle upon Tyne
NE1 4LP
England
United Kingdom
Website | http://www.newcastle-hospitals.org.uk |
---|---|
https://ror.org/05p40t847 |
Funders
Funder type
Industry
Bristol Myers-Squibb (USA)
Government organisation / For-profit companies (industry)
Government organisation / For-profit companies (industry)
- Alternative name(s)
- Bristol-Myers Squibb Company, BMS
- Location
- United States of America
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Basic results | No | No | |||
Results article | results | 12/07/2012 | 10/04/2019 | Yes | No |
Results article | results | 04/04/2013 | 10/04/2019 | Yes | No |
Editorial Notes
20/03/2020: EudraCT number added. Added EudraCT link to basic results (scientific).
10/04/2019: Publication reference added.